NCT02212886View on ClinicalTrials.gov

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

November 20, 2024

Conditions
Multiple Sclerosis
Interventions
DRUG

GA Depot 80 mg

Recruitment completed

DRUG

GA Depot 40 mg

Recruitment completed

Trial Locations (3)

Unknown

Barzilai Medical Center, Ashkelon

Rambam Medical Center, Haifa

TASMC, Tel Aviv

Sponsors

Lead Sponsor

Mapi Pharma Ltd.
All Listed Sponsors
lead

Mapi Pharma Ltd.

INDUSTRY

NCT02212886 - Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS | Biotech Hunter | Biotech Hunter